Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug has impacted its business.
Merck could still be a winning stock, despite the pharmaceutical company’s recent move to reprice one of its medications, Virtus Investment Partners chief market strategist Joe Terranova told CNBC’s ” Halftime Report ” on Monday. Terranova suggested … [1167 chars]
Source: CNBC | Published: 2026-02-02T22:30:58Z
Credit: CNBC
